A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia

Protocol No
JNJ-75276617ALE1001
Principal Investigator
Sameem Abedin
Phase
I
Summary
The purpose of this study is to see if a safe dose of JNJ-75276617 (the study drug) can be identified for treating participants with acute leukemia, including AML and ALL. Additional purposes include finding out if the study drug may be beneficial in treating acute leukemia, how long it stays in and acts on your body and how your body responds to it.
Description
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL